Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alinea Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Alinea Pharmaceuticals was founded recently around three in-licensed development programs, encompassing a Phase II-ready molecule to treat diabetic complications, a set of leads against a novel serum glucose-regulating target of significant interest to Big Pharma, and a research program around novel methods for lipid control.
Advertisement

Related Content

The Double-edged Sword of Diabetes Drug Development

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091028

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel